CTIC News and Press, CTI BioPharma Corp.

CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders PR Newswire SEATTLE , May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization ...

Shares of CTI BioPharma Corp. (NASDAQ: CTIC) traded at a new 52-week high today and are currently trading at $8.99. So far today, approximately 1.79M shares have been exchanged, as compared to an average 30-day volume of 10.16M shares. CTI BioPharma Corp., a biopharmaceutical company, focuses...

2023-05-22 11:17:03 ET Summary Sales beat: Despite Monjuvi's setbacks, MorphoSys exceeds Q1 2023 sales expectations with €62.3m and robust 11% YoY US growth. Pelabresib Potential: Accelerated MANIFEST-2 Pelabresib data readout could be a key catalyst, promising MF candidate...

NEW YORK, NY / ACCESSWIRE / May 16, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Franchise Group, Inc. (NASDAQ: FRG)'s ...

2023-05-16 16:26:55 ET Summary Acquisition: Sobi acquires CTI BioPharma for ~$1.7 billion, an 85% premium, aligning with Sobi's focus on hematology. Confidence: Main shareholder Investor AB's agreement to rights issue signifies deal confidence; no overlapping drugs between SOBI an...

NEW YORK, NY / ACCESSWIRE / May 14, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Arconic Corporation (NYSE: ARNC)'s s...

NEW YORK, NY / ACCESSWIRE / May 11, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Magenta Therapeutics, Inc. (NASD...

2023-05-10 17:35:39 ET CTI BioPharma ( NASDAQ: CTIC ) is scheduled to announce Q1 earnings results on Thursday, May 11th, after market close. The consensus EPS Estimate is -$0.12 and the consensus Revenue Estimate is $22.82M (vs. $2.3M last year). Over the last 3 month...

CTI BioPharma Corp. (NASDAQ: CTIC) is one today's most active stocks by volume. So far today, approximately 91.51M shares of CTI BioPharma Corp. have been exchanged, as compared to an average 30-day volume of 2.79M shares. CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquis...

2023-05-10 10:51:53 ET Shares of CTI BioPharma (NASDAQ: CTIC) were up more than 80% early Wednesday after the company announced it was getting bought out for $1.7 billion by Swedish Orphan Biovitrum AB (OTC: BIOVF) , also known as SOBI. CTI BioPharma specializes in targe...